Przerzutowy rak jelita grubego: badanie fazy III leku bevacizumab i cetuximab
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received…